Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD H WOOD

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1487099412
CMS profile
1032073
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$36,652.78

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD H WOOD

NPI 1487099412 · CMS profile ID 1032073

Allopathic & Osteopathic Physicians / Ophthalmology

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487099412?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD H WOOD, NPI 1487099412, CMS profile ID 1032073. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487099412?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EDWARD H WOOD, NPI 1487099412, CMS profile ID 1032073. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487099412?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EDWARD H WOOD, NPI 1487099412, CMS profile ID 1032073, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1487099412?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $36,652.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $292.2001/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453090 CMS
Genentech USA, Inc. $99.3401/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133005189 CMS
Apellis Pharmaceuticals, Inc. $17.8001/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154020379 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $573.51 7
PY2021 $6,000.57 15
PY2022 $21,415.95 34
PY2023 $36,143.14 45
PY2024 $36,652.78 53
PY2025 $9,144.45 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $260,254.49 206
PY2022 Principal investigator $5,771.97 2
PY2021 Principal investigator $22,147.87 5
PY2020 Principal investigator $39,201.28 3
PY2019 Recipient $3,177.32 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

206 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 12/31/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669988
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/31/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669996
Principal investigator 1 Boehringer Ingelheim International GmbH $237.60 12/31/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670008
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/31/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670010
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 12/31/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670016
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 12/18/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,790.32 12/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A 96-week single-arm controlled study to evaluate the efficacy and safety of 8mg Aflibercept in subjects with proliferative diabetic retinopathy (PDR) No dispute reported 06/30/2026 1184276528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $156.00 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.48 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.00 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275189
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 12/11/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669974
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 12/11/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669982
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/11/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670014
Principal investigator 1 Boehringer Ingelheim International GmbH $237.60 12/11/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670018
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/11/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670020
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/08/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669966
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/08/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669984
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 12/08/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669990
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 12/08/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670012
Principal investigator 1 ABBVIE INC. $12,162.00 12/04/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES PLLC
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202529086
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669956
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669958
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669960
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669964
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669968
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669970
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669972
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669976
Principal investigator 1 Boehringer Ingelheim International GmbH $202.50 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669978
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669980
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669986
Principal investigator 1 Boehringer Ingelheim International GmbH $237.60 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669992
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669994
Principal investigator 1 Boehringer Ingelheim International GmbH $237.60 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669998
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670000
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670002
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670004
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670006
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670022
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670024
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670026
Principal investigator 1 Boehringer Ingelheim International GmbH $249.75 12/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.05 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $742.50 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $310.50 12/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268145
Principal investigator 1 Boehringer Ingelheim International GmbH $1,831.95 11/27/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669944
Principal investigator 1 Boehringer Ingelheim International GmbH $5,668.65 11/27/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110,578.00 11/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A 96-week single-arm controlled study to evaluate the efficacy and safety of 8mg Aflibercept in subjects with proliferative diabetic retinopathy (PDR) No dispute reported 06/30/2026 1184264553
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,829.95 11/19/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262711
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 11/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669938
Principal investigator 1 Boehringer Ingelheim International GmbH $7,500.00 11/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669940
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 11/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669942
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 11/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669946
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669950
Principal investigator 1 Boehringer Ingelheim International GmbH $550.00 11/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669952
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 11/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669954
Principal investigator 1 Boehringer Ingelheim International GmbH $5,312.25 11/03/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669936
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670030
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670032
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 10/27/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 10/17/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 10/17/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251512
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 10/16/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23.94 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.15 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.74 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23.94 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 10/03/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184247200
Principal investigator 1 ABBVIE INC. $291.60 10/01/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202513004
Principal investigator 1 Apellis Pharmaceuticals, Inc. $5,000.00 09/26/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES PLLC
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio No dispute reported 06/30/2026 1250362562
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 09/05/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 08/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233046
Principal investigator 1 ABBVIE INC. $5,602.37 08/27/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506047
Principal investigator 1 Boehringer Ingelheim International GmbH $91.76 08/25/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220670038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 08/20/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184229273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,370.95 08/20/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184229275
Principal investigator 1 ABBVIE INC. $426.80 07/29/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202500414
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 07/28/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669918
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 07/28/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669920
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 07/28/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669922
Principal investigator 1 Boehringer Ingelheim International GmbH $146.16 07/28/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669924
Principal investigator 1 Boehringer Ingelheim International GmbH $3.66 07/28/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669926
Principal investigator 1 ABBVIE INC. $439.65 07/25/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES PLLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202499774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.46 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.16 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.74 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.74 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.74 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $170.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/24/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218279
Principal investigator 1 Boehringer Ingelheim International GmbH $540.00 07/18/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669876
Principal investigator 1 Boehringer Ingelheim International GmbH $235.00 07/18/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669912
Principal investigator 1 Boehringer Ingelheim International GmbH $40.13 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669878
Principal investigator 1 Boehringer Ingelheim International GmbH $15.69 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669880
Principal investigator 1 Boehringer Ingelheim International GmbH $15.40 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669882
Principal investigator 1 Boehringer Ingelheim International GmbH $16.77 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669884
Principal investigator 1 Boehringer Ingelheim International GmbH $20.51 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669886
Principal investigator 1 Boehringer Ingelheim International GmbH $285.27 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669888
Principal investigator 1 Boehringer Ingelheim International GmbH $47.25 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669890
Principal investigator 1 Boehringer Ingelheim International GmbH $8.33 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669892
Principal investigator 1 Boehringer Ingelheim International GmbH $5.67 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669894
Principal investigator 1 Boehringer Ingelheim International GmbH $4.33 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669896
Principal investigator 1 Boehringer Ingelheim International GmbH $4.33 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669898
Principal investigator 1 Boehringer Ingelheim International GmbH $31.50 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669900
Principal investigator 1 Boehringer Ingelheim International GmbH $19.67 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669902
Principal investigator 1 Boehringer Ingelheim International GmbH $8.33 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669904
Principal investigator 1 Boehringer Ingelheim International GmbH $19.67 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669906
Principal investigator 1 Boehringer Ingelheim International GmbH $5.67 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669908
Principal investigator 1 Boehringer Ingelheim International GmbH $156.33 07/17/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669910
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,358.45 06/27/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,526.20 06/27/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 06/27/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,638.60 06/27/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211959
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 05/28/2025 Non-covered Recipient Entity
AUSTIN RETINA ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184199893
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/21/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669932
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/21/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669934
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 05/01/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669868
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 05/01/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669870
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669872
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 05/01/2025 Non-covered Recipient Entity
Austin Retina Associates-Round Rock
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220669874